Professor Wang Yilong: Ischemic Stroke and Cerebrovascular Research Specialist
Professor Wang Yilong is a senior neurologist, professor, doctoral supervisor, executive vice president of Beijing Tiantan Hospital, and chief scientist of its Neurology Center. His clinical and research work focuses on ischemic stroke, transient ischemic attack, cerebral small-vessel disease, precision antiplatelet treatment, endovascular therapy research, and rare neurological disease.
Clinical and Academic Focus
- acute ischemic stroke;
- transient ischemic attack;
- secondary stroke prevention;
- precision antiplatelet treatment;
- CYP2C19-guided therapy;
- cerebral small-vessel disease;
- intracranial and extracranial atherosclerosis;
- stroke clinical trials; and
- second opinions after recurrent stroke.
Acute Ischemic Stroke
An ischemic stroke occurs when blood flow to part of the brain is blocked. Sudden facial droop, limb weakness, speech difficulty, vision loss, severe imbalance, or confusion requires immediate local emergency care.
Time-sensitive treatment can include intravenous thrombolysis and mechanical thrombectomy for eligible patients. International travel must never delay emergency imaging and treatment.
Transient Ischemic Attack
A transient ischemic attack, or TIA, causes temporary stroke-like symptoms without lasting infarction on some evaluations. Symptoms that disappear still require urgent assessment because early recurrent-stroke risk can be high.
Evaluation may include brain and vascular imaging, heart-rhythm monitoring, echocardiography, blood tests, and assessment of blood pressure, diabetes, cholesterol, smoking, and sleep apnea.
Dual Antiplatelet Treatment
Short-term treatment with two antiplatelet medicines can reduce early recurrent-stroke risk in selected patients with minor ischemic stroke or high-risk TIA. It also increases bleeding risk and is not appropriate for every patient or for indefinite use.
Professor Wang led major randomized studies, including CHANCE-2 and research evaluating dual antiplatelet treatment initiated within an extended early time window after ischemic stroke.
CYP2C19-Guided Therapy
Clopidogrel requires activation by the CYP2C19 enzyme. Some genetic variants reduce this activation and may limit its effect. CHANCE-2 studied ticagrelor-based treatment in patients carrying CYP2C19 loss-of-function variants after minor stroke or TIA.
Genetic results should be interpreted with diagnosis, bleeding risk, kidney and liver function, other medicines, and treatment availability. Patients should not change antiplatelet therapy without their stroke physician.
Stroke Cause and Secondary Prevention
Prevention should target the mechanism of the event. Possible causes include large-artery atherosclerosis, small-vessel disease, atrial fibrillation, heart disease, arterial dissection, inflammation, clotting disorders, or an undetermined source.
Treatment may include antiplatelet or anticoagulant medication, cholesterol and blood-pressure control, diabetes care, smoking cessation, rehabilitation, and selected vascular or cardiac procedures.
Cerebral Small-Vessel Disease
Small-vessel disease can appear on MRI as white-matter change, lacunes, microbleeds, enlarged perivascular spaces, or brain atrophy. It can contribute to stroke, gait difficulty, cognitive change, mood symptoms, and urinary problems.
Management focuses on vascular-risk control and careful interpretation of imaging. Extensive white-matter change alone does not establish the cause of every symptom.
Clinical Trials and Research
Professor Wang has led influential multicenter stroke trials published in major international journals. Participation in a clinical trial depends on exact inclusion criteria, timing, location, informed consent, and current recruitment status.
Who May Consider a Consultation?
- stable patients needing review after ischemic stroke or TIA;
- patients with recurrent stroke despite preventive treatment;
- patients with uncertain stroke mechanism;
- patients considering genetic guidance for antiplatelet treatment;
- patients with intracranial atherosclerosis or cerebral small-vessel disease;
- patients with conflicting recommendations about antiplatelet or anticoagulant therapy;
- patients seeking review of endovascular-treatment records; or
- patients assessing eligibility for a stroke clinical trial.
Medical Records to Prepare
- a precise symptom-onset and treatment timeline;
- brain CT and MRI in original DICOM format;
- CTA, MRA, carotid ultrasound, and catheter angiography;
- thrombolysis and thrombectomy records;
- ECGs, prolonged rhythm monitoring, and echocardiography;
- blood pressure, cholesterol, glucose, kidney, liver, blood-count, and coagulation results;
- CYP2C19 or other pharmacogenetic reports when available;
- all antiplatelet and anticoagulant treatment with dates and bleeding history;
- current neurological and rehabilitation assessments; and
- a clear list of prevention and recovery goals.
Planning an International Consultation
Any new stroke symptom requires immediate local emergency assessment, even if it resolves. Stable patients should confirm whether original imaging and treatment records can be reviewed.
Remote medical-record review requires physician authorization. Final medication recommendations may require in-person examination, repeat imaging, cardiac testing, and laboratory assessment.
How CMCS Can Assist
CMCS – China Medical Concierge Shanghai is an independent medical concierge and health management company, not a hospital. We assist international patients with organizing and translating stroke records, identifying an appropriate specialist, requesting appointment availability, arranging interpretation, and planning medical travel in China.
Access to Professor Wang, remote review, admission, genetic testing, or a clinical trial is subject to doctor and hospital approval. CMCS does not guarantee appointments, treatment eligibility, trial enrollment, or clinical outcomes.
- Email: contract@medicalsh.com
- WhatsApp: Contact us on WhatsApp
- Website: www.medicalsh.com
Important Note
Doctor titles, clinical roles, testing, medicines, trial availability, and appointment arrangements may change. This profile is based on the supplied verified research document and is for general information only. It does not replace assessment by a qualified stroke team.
0 comments